Cooks Tomer, Schmidt Michael, Bittan Hadas, Lazarov Elinor, Arazi Lior, Kelson Itzhak, Keisari Yona
Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):966-73. doi: 10.1016/j.ijrobp.2009.02.063.
Diffusing alpha-emitters radiation therapy (DART) is a new form of brachytherapy enabling the treatment of solid tumors with alpha radiation. The present study examines the antitumoral effects resulting from the release of alpha emitting radioisotopes into solid lung carcinoma (LL2, A427, and NCI-H520).
An in vitro setup tested the dose-dependent killing of tumor cells exposed to alpha particles. In in vivo studies, radioactive wires (0.3 mm diameter, 5 mm long) with (224)Ra activities in the range of 21-38 kBq were inserted into LL/2 tumors in C57BL/6 mice and into human-derived A427 or NCI-H520 tumors in athymic mice. The efficacy of the short-lived daughters of (224)Ra to produce tumor growth retardation and prolong life was assessed, and the spread of radioisotopes inside tumors was measured using autoradiography.
The insertion of a single DART wire into the center of 6- to 7-mm tumors had a pronounced retardation effect on tumor growth, leading to a significant inhibition of 49% (LL2) and 93% (A427) in tumor development and prolongations of 48% (LL2) in life expectancy. In the human model, more than 80% of the treated tumors disappeared or shrunk. Autoradiographic analysis of the treated sectioned tissue revealed the intratumoral distribution of the radioisotopes, and histological analysis showed corresponding areas of necrosis. In vitro experiments demonstrated a dose-dependent killing of tumors cells exposed to alpha particles.
Short-lived diffusing alpha-emitters produced tumor growth retardation and increased survival in mice bearing lung tumor implants. These results justify further investigations with improved dose distributions.
扩散性α粒子发射体放射治疗(DART)是一种新型近距离放射治疗方法,能够利用α辐射治疗实体肿瘤。本研究考察了将发射α粒子的放射性同位素释放到实体肺癌(LL2、A427和NCI-H520)中所产生的抗肿瘤效果。
体外实验装置测试了暴露于α粒子的肿瘤细胞的剂量依赖性杀伤情况。在体内研究中,将具有21 - 38 kBq活度的(224)Ra放射性金属丝(直径0.3 mm,长5 mm)插入C57BL/6小鼠的LL/2肿瘤以及无胸腺小鼠的人源A427或NCI-H520肿瘤中。评估了(224)Ra的短寿命子体产生肿瘤生长延缓和延长生存期的效果,并使用放射自显影术测量了放射性同位素在肿瘤内的扩散情况。
将一根DART金属丝插入6至7 mm肿瘤的中心对肿瘤生长有显著的延缓作用,导致肿瘤发展受到显著抑制,LL2肿瘤抑制率为49%,A427肿瘤抑制率为93%,预期寿命延长48%(LL2)。在人体模型中,超过80%的治疗肿瘤消失或缩小。对处理后的切片组织进行放射自显影分析揭示了放射性同位素在肿瘤内的分布,组织学分析显示了相应的坏死区域。体外实验证明了暴露于α粒子的肿瘤细胞的剂量依赖性杀伤。
短寿命的扩散性α粒子发射体使荷肺肿瘤植入物的小鼠肿瘤生长延缓并提高了生存率。这些结果证明进一步研究改善剂量分布是合理的。